

February 14, 2020

The Manager, Listing Department The National Stock Exchange of India Ltd. Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai - 400 051 NSE Symbol : PANACEABIO BSE Limited Corporate Relationship Department, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001 BSE Scrip Code: 531349

Reg.: Outcome of Board Meeting

Dear Sir/Madam,

In continuation to our letter dated February 05, 2020 and pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR Regulations"), we would like to inform you that the Board of Directors of the Company has, at its meeting held today, i.e. February 14, 2020, inter-alia, considered and approved the following:-

- Unaudited Standalone and Consolidated Financial Results (Provisional) of the Company (which have been subjected to Limited Review by the Statutory Auditors) for the quarter and nine months ended December 31, 2019 in terms of Regulation 33 of SEBI LODR Regulations. The same were also reviewed by the Audit Committee in its meeting held earlier on February 14, 2020. A copy of the same along with the Limited Review Report is enclosed herewith as Annexure – A;
- Subject to the approval of the Shareholders of the Company, Panacea Biotec Limited -Employee Stock Option Plan 2020 ("ESOP 2020"/ "Plan") for the Employees of the company and its subsidiary company; and
- 3. An Extraordinary General Meeting of the Company will be held on Saturday, March 28, 2020 at 11:30 A.M. at the Registered Office of the Company at Ambala Chandigarh Highway, Lalru 140 501, Punjab for approval of the aforesaid ESOP 2020.

Further, pursuant to Regulation 46(2)(1) of SEBI LODR Regulations, the above said financial results are being uploaded on the website of the Company i.e. www.panaceabiotec.com.

The Extract of Statement of above said financial results for the quarter and nine months ended December 31, 2019 in the Format as prescribed in Annexure I of SEBI Circular No. CIR/CFD/FAC/62/2016 dated 05.07.2016 is also being sent for publication in newspapers pursuant to Regulation 47(1)(b) of SEBI LODR Regulations.

Contd..2/-



B1 Extn. /G3, Mohan Co-op Indl. Estate, Mathura Road, New Delhi -110044 Email: vinodgoel@panaceabiotec.com Phone: D.I.D. +91-11-4167 9015 Fax: +91-11-4167 9070

CIN: L33117PB1984PLC022350 Registered Office: Ambala-Chandigarh Highway, Lalru - 140 501, Punjab, India. Ph.: +91-1762-505900, Fax: +91-1762-505906. e-mail: corporate@panaceabiotec.com website: www.panaceabiotec.com

Panacea Biotec Ltd.

The meeting of the Board of Directors commenced at 02:00 P.M. and concluded at 5:40 P.M.

We request you to kindly bring the above information to the notice of your members.

Thanking you,

Sincerely yours, for **Panacea Biotec Ltd.**

Vich

Vinod Goel Group CFO and Head Legal & Company Secretary Encls: As above.

Bior Pan









	Q3FY2	2020	9MFY	2020	
Consoliated:	Rs. Cr	Growth%*	Rs. Cr	Growth%*	
income from operations	167.74	52%	418.70	27%	
EBITDA	36.98	45%	87.64	not measurable**	
compared to corresponding period of F	FY2019	-		**EBITDA for 9M2019 was n	egative

Committed to affordable treatment for All

We enable better Health to Live Well, Live Longer Innovation at

heart

(Rs. in Lakh except per share) Extract of Standalone and Consolidated Financial Results (Unaudited) for the Quarter and Nine months ended December 31, 2019 Consolidated Particulars Standalone Quarter ended Nine months ended Year Ended **Ouarter ended** Nine months ended Year Ended December September December December December March 31, December September December December December March 31, 31, 2019 30, 2019 31. 2019 30, 2019 31, 2018 31, 2019 31, 2018 2019 31, 2018 31, 2019 31, 2018 2019 Unaudited Unaudited Unaudited Audited Unaudited Unaudited Unaudited Unaudited Unaudited Audited Unaudited Unaudited 32,999 45,670 Total income from operations 5,552 2,098 2,927 10,132 6,695 9,621 16,774 12,518 11,038 41,870 Net Profit / (Loss) for the period (before tax, exceptional and/or 105 (5,511) (896) (9,675) (11,187 (28,554) (3.915)(3.585)(5,691) (13,864) (28,080) (1,790) extraordinary item) Net Profit / (Loss) for the period before tax (after exceptional and/or 105 (5,455) (3,585) 3,255 (1,783) (7,048) (897) (11,198) (13,865) 4,862 (7,231) (18,614) extraordinary item) (14,376) Net Profit / (Loss) for the period after tax (after exceptional and/or (126) (5,695) (3,851) (7,958) (19,412) 2.194 (2,014) (7,283) (1,387) (11,947) 4,091 extraordinary item) of continuing operations (324) (218) (207) (512) (444) Net Profit / (Loss) for the period after tax (after exceptional and/or (1,848) (1,470) 1,550 (4,102) 3,679 463 (118) extraordinary item) of discontinued operations Total comprehensive income for the period (comprising of profit/(loss) (1,944) (7,154) (2,336) (15, 839)2,592 (2,031) (7,443) (1,629) (12,317) (14,926) 3,721 (12,035) for the period.(after tax) and other comprehensive income (after tax)) 613 Equity Share Capital (face value of Re.1 per share) 613 613 613 613 613 613 613 613 613 613 613 Earning per Share (of Re.1 each (annualised, other than guarters & nine months) (23.47) Basic and Diluted - continuing operations (0.21) (9.30) (6.29) (12.99)(31.69) 3.58 (3.29)(11.89) (2.26) (19.51) 6.68 (0.84) (0.72)(0.53)Basic and Diluted - discontinued operations (3.02) (2.40) 2.53 (6.70) 6.01 0.76 (0.19) (0.36) (0.34)

Notes:

1 The above is an extract of the detailed format of Quarterly and Nine months ended Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly and Nine months ended Financial Results is available on the Stock Exchanges websites, NSE- http://www.nseindia.com, BSE- http://www.bseindia.com and is also available on the Company's website, http://www.panaceabiotec.com.

2 The above financial results were reviewed by the Audit Committee of the Board and approved by the Board of Directors at their respective meetings held on February 14, 2020.

3 The financial results have been prepared in accordance with the recognition and measurement principles of applicable Indian Accounting Standard ("IND-AS") notified under the Companies (Indian Accounting Standards) Rules, 2015 as specified in section 133 of the Companies Act, 2013.

4 Previous period / year amounts have been regrouped/ reclassified to make them comparable with those of current period/year.

Place: New Delhi Date: February 14, 2020 For and on behalf of the Board

Delhi

Managing Director

Dr. Rajesh Jain

Panacea Biotec Limited

Regd. Office : Ambala-Chandigarh Highway, Lalru- 140501, Punjab

CIN: L33117PB1984PLC022350 - Ph. No. 91-11-41679000, Fax: 91-11-41679070, Website: http://www.panacea-biotec.com, E-mail: Corporate@panaceabiotec.com

Constraint Sa, 2003		nacea Biotec					ent of Standald or the Quarter			cember 31, 203	19		(Rs. in Lak	h except pe
Under terminal Curver ended The montter ended T					Stand	alone		Consolidated						
Increment 13, 2019 13, 2019 13, 2019 13, 2018 20.19 13, 2018 20.19 13, 2018 20.10 13, 2018 20.20 13, 2018 20.20 13, 2018 20.20 13, 2018 20.2018 <t< th=""><th>3.140</th><th>1.01.000</th><th></th><th colspan="3"></th><th colspan="2">Nine months ended</th><th></th><th>Quarter ended</th><th>1</th><th>Nine mor</th><th>nths ended</th><th>Year e</th></t<>	3.140	1.01.000					Nine months ended			Quarter ended	1	Nine mor	nths ended	Year e
Instruction ja. 2019			December	September	December	December	December	March 31,	December	September	December	December	December	Marc
Income Unaudited Unaudited Unaudited Unaudited Unaudited Unaudited Network Refer note 3 Unaudited						31, 2019		2019	31, 2019	30, 2019	31, 2018	31, 2019	31, 2018	201
a) evenue from operations 5.552 2.098 2.227 10.132 6.658 9.212 15.774 12.238 13.770 B) Other income 5.668 2.175 2.299 10.439 6.292 9.374 17.097 12.268 11.387 43.041 1 Constraints 2.083 2.777 1.430 5.255 3.077 5.592 2.701 13.266 B) proclass of trade goods, incrude 1.138 1.1487 4.3041 1.2749<						Unaudited	Unaudited	Audited	Unaudited	Unaudited	Refer note 3	Unaudited	Refer note 3	Audi
a) evenue from operations 5.552 2.098 2.227 10.132 6.658 9.212 15.774 12.238 13.770 B) Other income 5.668 2.175 2.299 10.439 6.292 9.374 17.097 12.268 11.387 43.041 1 Constraints 2.083 2.777 1.430 5.255 3.077 5.592 2.701 13.266 B) proclass of trade goods, incrude 1.138 1.1487 4.3041 1.2749<														
b) present in moment 116 17 112 307 224 353 323 345 339 1,171 III Exponding 5,666 2,175 2,399 10,489 9,774 11,837 43,404 11,374 43,404 11,374 43,404 11,374 43,404 11,374 43,404 11,374 43,404 11,374 43,404 11,374 43,404 11,374 43,404 11,374 43,404 11,374 43,404 11,373 5,477 5,592 2,701 13,626 11,373 11,016 1,773 11,665 1,773 11,38 911 3,370 2,779 4,116 3,670 3,548 3,313 10,428 1,216 1,317 1,318 911 7,276 3,203 1,073 1,108 5,116 3,317 1,048 5,1265 3,137 1,216 3,117 1,108 5,116 3,117 1,108 5,116 5,116 3,117 1,108 5,116 5,117 1,108 5,116 5,	1		5 552	2 098	2,927	10.132	6.695	9,621	16,774	12,518	11,038	41,870	32,999	4
B) Continue 5,668 2,175 2,99 10,489 6,929 9,974 17,677 12,263 11,367 43,041 31 B Constrained 2,083 2,777 1,480 5,526 3,077 5,933 5,477 5,592 2,701 13,626 B) Public constance of finished goods, (139) (1,789) (225) (2,121) (449 1,730 (616) (2,171) (456) (2,745) B) public constance of finished goods, (139) (1,789) (225) (2,122) (4,151) 3,670 3,548 3,153 (0,02) (1,780) (2,35) (2,077) (4,154) 3,670 3,548 3,153 (0,02) (1,474) (3,237) (1,474) (1,425) (2,745) (1,484) (2,235) (1,310) (2,770) (1,543) (2,774) (3,237) (1,310) (2,770) (1,543) (1,344) (2,237) (1,344) (2,345) (1,344) (2,345) (1,344) (2,345) (1,344) (2,345) (1,343) <th< td=""><td></td><td>•</td><td></td><td>1</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>797</td><td></td></th<>		•		1									797	
Idea Instance Land Land <thland< th=""> Land <thland< th=""> Land <thland< th=""></thland<></thland<></thland<>		· · · · · · · · · · · · · · · · · · ·											33,796	4
a) Cost of raw and packing materials consumed 2,083 2,779 1,480 5,257 2,702 1,34,86 b) Aurchase of trade goods - <			3,000	2,275	2,555	10,100	-,							
a) Loss of ray many backing intermet construct Loss	1 "		2 083	2 779	1 4 3 0	5,256	3.077	5,913	5,477	5,592	2,701	13,626	6,611	
b) Purchase of Instance goods, work-in-progress and Stock-In-Lade (128) (1,780) (235) (2,125) 449 1,730 (G16) (2,712) (456) (2,745) a) Depreciations and stock-In-Lade 1,231 1,138 941 3,370 2,797 4,116 3,670 3,548 3,153 10,428 11 a) Operations and stock-In-Lade 173 1,33 2,223 349 8,111 10,663 4,724 4,448 12,925 12,263 3,237 12,2263 5,756 6,699 6,524 16,130 13,857 13,857 13,857 13,864 12,864 12,858 2,794 14,857 14,2263 52,766 6 6,675 16,130 13,864 12,864 13,857 13,874 12,263 52,766 6 6,772 78 13,874 12,263 52,766 6 7 7 3 13 7 Total sepones 105 (5,915) (5,651) (1,364) (2,800) (1,798) (5,598) (6,797) 11			2,005	2,5	2,100	5,255	-,	-,				843	653	
c) (Langes in interiority unitation (2007) (1.201 <td< td=""><td></td><td></td><td>-</td><td>(1 700)</td><td>(225)</td><td>(2 125)</td><td>449</td><td>1 730</td><td>Contraction and</td><td></td><td></td><td>sport and the</td><td>2,071</td><td></td></td<>			-	(1 700)	(225)	(2 125)	449	1 730	Contraction and			sport and the	2,071	
d) Employee bonefits sepence 1,231 1,138 941 3,270 2,273 4,116 3,578 3,518 10,428 3,171 e) Depreciation and amotivation expense 173 133 2,223 349 8,111 10,463 4,774 4,146 (1,414) 12,952 e) Other expenses (net) 1,551 3,515 6,70 5,663 6,990 6,524 15,10 20,773 38,054 18,877 12,374 14,2255 5,563 6,990 6,524 15,10 20,773 38,054 18,877 12,375 20,775 6 III Profit/(Los) lefore share of pint venture, exceptional and extra-ordinary items and tax (1-1) 105 (3,515) (5,563) (13,364) (28,600) (1,783) (5,568) (897) (5,568) (897) (11,540) - (1,540) - (1,540) - (1,540) - (1,540) - (1,540) - (1,540) - (1,540) - (1,540) - (1,540) - (1,540) -			(189)	(1,780)	(255)	(2,123)	443	1,750	(010)	(2,171)	(450)	(2,745)		1
a) imployee benefits before 1col (1) mployee benefits before (1) mployee benefits before (1) mployee benefits before (1) mployee benefits benefits (1) mployee benefits benefits (1) mployee benefits benefits (1) mployee benefits (1) method (1) method (1 1 2 0	041	3 370	2 070	4 116	2 670	3 548	3 153	10 478	10,900	
e) Oppression Registre 173 133 2,223 1349 8,111 10,663 4,724 4,148 (1,144) 12,2952 g) Other segmes (nc) 5,563 6,090 6,574 16,130 20,733 38,654 11,887 12,265 5,881 37,74 22,223 (1,887) (1,8,87) 12,265 5,881 37,74 22,224 (1,90) (5,513) (8,969) (6,779) (6,551) (1,8,864)													7,913	1
1) finance cost 1,553 3,551 671 7,746 3,727 12,529 4,192 5,881 2,794 14,225 12,746 3,727 12,529 4,192 5,881 2,794 14,226 5,757 12,529 4,192 5,881 2,794 14,226 5,757 6 111 Portfl(kos) before share of joint venture, exceptional and exta-(H) 105 (3,915) (3,585) (5,691) (13,864) (28,080) (1,790) (5,511) (899) (9,675) (1 V Store opticit/(sos) all optic venture accounted for using equity method - - - 7 3 (11) 17 V Exceptional terms - (1,540) - (1,540) - (1,540) - (1,540) - (1,540) - (1,540) - (1,540) - (1,540) - (1,540) - (1,540) - (1,540) - (1,540) - (1,540) - (1,540) - (1,540) - (1,540)		e) Depreciation and amortisation expense	1000 CONTRACTOR		1000				10 C C C C C C C C C C C C C C C C C C C				4,065	
B Charle segments Constance Constance <thconstance< th=""> Constance <thco< td=""><td></td><td>f) Finance cost</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>12,770</td><td></td></thco<></thconstance<>		f) Finance cost											12,770	
Instruction		g) Other expenses (net)				and the second second second second	and the second						44,983	
III Profit (Loss) lation stand to X [47] Profit (Loss) lation stand to X [47] Profit (Loss) lation stand to X [47] IV Share of profit (Loss) lation stand to X [47] III III IIII IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII		Total expenses												
IV Share of profit/(loss) of a joint venture accounted for using equity method equity equity sha	ш		105	(3,915)	(3,585)	(5,691)	(13,864)	(28,080)	(1,790)	(5,511)	(896)	(9,675)	(11,187)	
V Profit/(Loss) before exceptional and extra-ordinary items 105 (3,515) (3,585) (5,691) (13,680) (1,783) (5,508) (1,783) (5,508) (1,783) (7,504) (1,540) - (1,540) 1 (1,542) (1,543) (1,1470) 1,550 (2,512) (1,541) (1,212) (1,541) (1,218) (1,470) 1,550 (4,102) 3,679 463 (118) (2,128) (2,128) (2,128) (2,128) (1,218) (1,2459) (118) (1,218) (2,129) (1,533)	ıv	Share of profit/(loss) of a joint venture accounted for using	-	-	•	-	-	-	7	3	(1)	17	6	
VI Exceptional terms - (1,540) - - - - - - - 100 0 - - 100 0 - - 100 0 - 100 0 -	v		105	(3,915)	(3,585)	(5,691)	(13,864)	(28,080)	(1,783)	(5,508)	(897)	(9,658)	(11,181)	
VI Exceptional terms 105 (5,455) (7,23) (12,614) 3,255 (1,783) (7,7048) (897) (11,198) (1 VII Profit/(Loss) before Tax (net) - - - - - 772 798 313 231 235 500 749 VII Profit/(Loss) before Tax (net) - - - - - - 772 798 313 231 235 500 749 Total tax expenses 231 240 266 727 798 10,61 231 235 400 749 VII Profit/(Loss) before tax for the period (for continuing operations) (VI-VII) (12,648) (1,470) 1,550 (4,102) 3,679 463 (95) (259) (207) (513) X Tax expense of discontinued operations (1,848) (1,470) 1,550 (4,102) 3,679 463 (118) (218) (207) (512) XII Net Profit/(Loss) after tax for the period from discontinued (1,848) (1,470) 1,550 (4,102) 3,679 463 <td></td> <td>and tax (III+IV)</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>4 5 4 9</td> <td></td> <td>10 5 401</td> <td>12 604</td> <td></td>		and tax (III+IV)								4 5 4 9		10 5 401	12 604	
VIII Profit(Loss) before tax (vet) -	VI	Exceptional items			-				-		-		(2,684)	
a) Current tax (net) - - - - - - 745 0 - (10) 0 b) Deferred tax 231 240 266 727 798 313 231 235 500 749 Total tax expenses 231 240 266 727 798 1,061 231 235 490 749 operations) (VII-VIII) (I)	VII	Profit/(Loss) before Tax (V+VI)	105	(5,455)	(3,585)	(7,231)	(18,614)	3,255	(1,783)	(7,048)	(897)	(11,198)	(13,865)	7
a) Current dax (itely) 231 240 266 727 798 313 231 235 500 749 Total tax expenses 231 240 266 727 798 1,061 231 235 490 749 IX Net Profit/(Loss) after tax for the period (for continuing operations) (II)-VIII) (11,26) (5,695) (3,851) (7,958) (15,412) 2,194 (2,014) (7,283) (11,397) (11,977) (VIII	Tax expense:												1
b) Deferred tax 231 231 230 2266 727 798 313 231 235 500 749 Total tax expenses 231 240 266 727 798 1,061 231 235 490 749 IX Net Profit/(Loss) after tax for the period (for continuing operations) (VII-VIII) (11,947) (12,947) (12,948) (14,702) 3,679 463 (118) (219) (211,947) (12,947) (12,947) (12,947) (12,948) (12,948) (12,948) (12,948) (12,948) (12,948) (12,948)	100,000		-	-	-	-	-			-			77	
Total tax sepenses 231 240 266 727 798 1,061 231 235 490 749 IX Net Profit/(Loss) after tax for the period (for continuing coperations) (VII-VIII) (126) (5,695) (3,851) (7,958) (19,412) 2,194 (2,014) (7,283) (1,1947)<			231	240	266	727	798	313	2003000				434	
IX Net Profit/(Loss) after tax for the period (for continuing operations) (VII-VIII) (1,267) (1,269) (3,851) (7,958) (19,412) 2,194 (2,014) (7,7283) (1,387) (11,947) (1,1947)			231	240	266	727	798		A CONTRACTOR OF				511	
X Net Profit/(Loss) before tax from discontinued operations (1,848) (1,470) 1,550 (4,102) 3,679 463 (95) (259) (207) (513) XI Tax expense of discontinued operations - - - - 23 (41) - (1) XII Net Profit/(Loss) after tax for the period from discontinued (1,470) 1,550 (4,102) 3,679 463 (118) (218) (207) (512) VII Net Profit/(Loss) after tax for the period from continuing and (1,974) (7,165) (2,301) (12,060) (15,733) 2,657 (2,132) (7,501) (1,594) (12,459) (1 XIV Other comprehensive income: (1) <td>IX</td> <td>Net Profit/(Loss) after tax for the period (for continuing</td> <td>(126)</td> <td>(5,695)</td> <td>(3,851)</td> <td>(7,958)</td> <td>(19,412)</td> <td>2,194</td> <td>(2,014)</td> <td>(7,283)</td> <td>(1,387)</td> <td>(11,947)</td> <td>(14,376)</td> <td>7</td>	IX	Net Profit/(Loss) after tax for the period (for continuing	(126)	(5,695)	(3,851)	(7,958)	(19,412)	2,194	(2,014)	(7,283)	(1,387)	(11,947)	(14,376)	7
X Tetr Fronty (1007) (2017) (2017) (2017) (2017) (2017) (2017) 1,1 1,1 - - 23 (41) - (1) XI Tax expense of discontinued operations (1,470) 1,550 (4,102) 3,679 463 (118) (218) (207) (512) XIII Net Profty (Loss) after tax for the period from continuing and discontinued operations (X+XI) (1,974) (7,165) (2,301) (12,060) (15,733) 2,657 (2,132) (7,501) (1,594) (12,459) (1,573) XIV Other comprehensive income: (1,61) (7) 19 (14) 57 35 (12) (10) 19 (14) b) i) Items that will no the reclassified to Profit or Loss - - - 8 36 - 117 ii) Income Tax related to above (1,944) (7,154) (2,336) (12,035) (15,839) 2,592 (2,031) (7,443) (1,623) (12,317) (1,61) VV Total comprehensive income for the period (XIII+XIV) (1,944) (7,154) (2,336) (12,035) (15,839) 2,592 (2,031) (7	.	Not Profit // locs) before tax from discontinued operations	(1.848)	(1,470)	1,550	(4,102)	3,679	463	(95)	(259)	(207)	(513)	(444)	
XII Net Profit/(Loss) after tax for the period from discontinued operations (X-XI) (1,848) (1,470) 1,550 (4,102) 3,679 463 (118) (218) (207) (512) XII Net Profit/(Loss) after tax for the period from continuing and discontinued operations (X-XI) (1,974) (7,165) (2,301) (12,060) (15,733) 2,657 (2,132) (7,501) (1,594) (12,459) (7,501) XIV Other comprehensive income: (1) (1) (10) 32 32 (54) 39 i) Items that will not be reclassified to Profit or Loss 46 18 (54) 39 (163) (100) 32 32 (54) 39 ii) Income tax related to above (16) (7) 19 (14) 53 (12) (10) 19 (14) b) i) Items that will be reclassified to Profit or Loss - - - - - - - - - - - - 117 - - - - - - - - - - - -				-	-	-	-	-	23	(41)	-	(1)	-	
Note From (Loss) after tax for the period non-continuing and discontinued operations (X+XI) (1,574) (7,501) (1,594) (12,459) (1,573) XIII Net Profit/(Loss) after tax for the period from continuing and discontinued operations (X+XI) (1,974) (7,165) (2,301) (12,060) (15,733) 2,657 (2,132) (7,501) (1,594) (12,459) (1,573) a) 1) terms that will not be reclassified to Profit or Loss 46 18 (54) 39 (163) (100) 32 32 (54) 39 ii) Income tax related to above (16) (7) 19 (14) 57 35 (12) (10) 19 (14) b) 1) terms that will be reclassified to Profit or Loss - - - 81 36 - 17 ii) Income Tax related to above - - - - - - 17 XV Total comprehensive income attributable to: -<			(1.848)	(1.470)	1.550	(4.102)	3,679	463	(118)	(218)	(207)	(512)	(444)	
XIII Net Profit/(Loss) after tax for the period from continuing and discontinued operations (IX+XII) (1,974) (7,165) (2,301) (12,060) (15,733) 2,657 (2,132) (7,501) (1,594) (12,459) (1,573) XIII Net Profit/(Loss) after tax for the period from continuing and discontinued operations (IX+XII) 1	XII		(2,010)	(_,,	-,									
XIII Net Print (Loss) are tax for the period from continuing and discontinued operations (XF-XII) (1,1,2,3,1) <		operations (X-XI)	(1 974)	(7.165)	(2,301)	(12.060)	(15,733)	2.657	(2.132)	(7,501)	(1,594)	(12,459)	(14,820)	
XIV Other comprehensive income: 46 18 (54) 39 (163) (100) 32 32 (54) 39 i) Items that will not be reclassified to Profit or Loss (16) (7) 19 (14) 57 35 (12) (10) (10) (14) b) i) Items that will be reclassified to Profit or Loss - - - 81 36 - 117 ii) Income Tax related to above -	XIII		(1,574)	(,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	(_,_,_,_,		,,,							1
a) i) Items that will not be reclassified to Profit or Loss 46 18 (54) 39 (163) (100) 32 32 (54) 39 ii) Income tax related to above (16) (7) 19 (14) 57 35 (12) (10) 19 (14) b) i) Items that will be reclassified to Profit or Loss - - - - 81 36 - 117 ii) Income Tax related to above - - - - - - - - - - 10 10 117 117 ii) Income Tax related to above - - - - - - - - - 10 10 117 117 XV Total comprehensive income for the period (XIII+XIV) (1,944) (7,154) (2,336) (12,035) (15,839) 2,592 (2,031) (7,443) (1,623) (12,319) (1 XVI Total comprehensive income attributable to: - - - - - 00 2 (6) 2 XVII														1
a) i) them sthat will not be reclassified to profit of Loss 40 10 (10) 10 (10) 19 (14) ii) Income tax related to above (16) (7) 19 (14) 57 35 (12) (10) 19 (14) b) i) Items that will be reclassified to Profit or Loss - - - - 81 36 - 117 ii) Income Tax related to above -	1000		46	18	(54)	39	(163)	(100)	32	32	(54)	39	(163)	
II) Income tax leaded to added ICA	a)					1					Concerned in		57	1
b) i) thems that will be reclassified to Price to the period (XIII+XIV) ii) Income Tax related to above -			(10)		15	(14)		-			-		-	1
XV Total comprehensive income for the period (XIII+XIV) (1,944) (7,154) (2,336) (12,035) (15,839) 2,592 (2,031) (7,443) (1,629) (12,317) (1 XVI Total comprehensive income attributable to: i) owners of the Company (1,944) (7,154) (2,336) (12,035) (15,839) 2,592 (2,031) (7,443) (1,623) (12,317) (1 XVI Total comprehensive income attributable to: i) owners of the Company (1,944) (7,154) (2,336) (12,035) (15,839) 2,592 (2,031) (7,443) (1,623) (12,317) (1 WI Paid-up equity share capital 613 61	b)		-						-	-			-	1
XV Total comprehensive income for the period (kill kill) (1,244)			11 000	17 154	(2 226)	(12 025)	(15 830)	2 592	(2 031)	(7 443)	(1.629)	(12.317)	(14,926)	
i) owners of the Company (1,944) (7,154) (2,336) (12,035) (15,839) 2,592 (2,031) (7,445) (1,623) (12,319) (1,7154) ii) Non-controlling interests - - - (0) 2 (6) 2 XVII Paid-up equity share capital 613 <td>xv</td> <td></td> <td>(1,944)</td> <td>(7,154)</td> <td>(2,550)</td> <td>(12,035)</td> <td>(13,035)</td> <td>2,552</td> <td>(2,051)</td> <td>(,,-,,)</td> <td>(2,020)</td> <td>(</td> <td>(2.,220)</td> <td>1</td>	xv		(1,944)	(7,154)	(2,550)	(12,035)	(13,035)	2,552	(2,051)	(,,-,,)	(2,020)	((2.,220)	1
i) owners of the Company (1,944) (7,154) (2,336) (12,035) (15,839) 2,592 (2,031) (7,445) (1,623) (12,319) (1,623) ii) Non-controlling interests - - - - 0) 2 (6) 2 XVII Paid-up equity share capital 613 614	XVI	Total comprehensive income attributable to:									10 0000	140.040	114 0000	
II) Non-Controlling interests 613	-	i) owners of the Company	(1,944)	(7,154)	(2,336)	(12,035)	(15,839)	2,592					(14,996)	
XVII Paid-up equity share capital 613	*	ii) Non-controlling interests	-	-	-	-	-	-					70	1
XVIII Earning per share for continuing operations (of Re. 1/- each), (annualised, except for quarters & nine months) (0.21) (9.30) (6.29) (12.99) (31.69) 3.58 (3.29) (11.89) (2.26) (19.51) XIX Earning per share for discontinued operations (of Re. 1/- (0.21) (9.30) (6.29) (12.99) (31.69) 3.58 (3.29) (11.89) (2.26) (19.51)	XVII	Paid-up equity share capital	613	613	613	613	613	613	613	613	613	613	613	
(annualised, except for quarters & nine months) (0.21) (9.30) (6.29) (12.99) (31.69) 3.58 (3.29) (11.89) (2.26) (19.51) XIX Earning per share for discontinued operations (of Re. 1/- (11.99) (31.69) 3.58 (3.29) (11.89) (2.26) (19.51)	A	Earning per share for continuing operations (of Re. 1/- each),												1
Basic and Diluted (in Rs.) (0.21) (9.30) (6.29) (12.99) (31.69) 3.58 (3.29) (11.89) (2.26) (19.51) XIX Earning per share for discontinued operations (of Re. 1/- (0.21) (9.30) (6.29) (12.99) (31.69) 3.58 (3.29) (11.89) (2.26) (19.51)		(annualised, except for guarters & nine months)												1
XIX Earning per share for discontinued operations (of Re. 1/-			(0.21)	(9 30)	(6.29)	(12.99)	(31,69)	3.58	(3,29)	(11.89)	(2.26)	(19.51)	(23.47)	
XIX Earning per share for discontinued operations (of Re. 1/-			(0.21)	(5.50)	(0.25)	(12.55)	(52.05)	2.00	,	,,	,/			
leach), (annualised, except for quarters & nine months)	XIX	Earning per share for discontinued operations (of Ke. 1/-											1	
	1	each), (annualised, except for quarters & nine months)						0.75	10.101	10.20	10.241	(0.04)	10 73	
Basic and Diluted (in Rs.) (3.02) (2.40) 2.53 (6.70) 6.01 0.76 (0.19) (0.36) (0.34) (0.84)		Basic and Diluted (in Rs.)	(3.02)	(2.40)	2.53	(6.70)	6.01	0.76	(0.19)	(U.36)	(0.34)	(0.84)	(0.72)	

Statement of Standalone and Consolidated Financial Results (Unaudited) for the Quarter and Nine months ended December 31, 2019

		Unaudi	ted Segment-v	vise nevenue,	nesures and C		cu					(Rs. in Lak
Particulars			Stand	alone				Consoli	idated			
	Quarter ended			Nine months ended Year ended			Quarter ended			Nine months ended		Year ended
	December	September	December	December 31, 2019	December	March 31, 2019	December	September 30, 2019	December	December 31, 2019	December	March 31
	31, 2019 Unaudited	30, 2019 Unaudited	31, 2018 Unaudited	Unaudited	31, 2018 Unaudited	Audited	31, 2019 Unaudited	Unaudited	31, 2018 Refer note 3	Unaudited	31, 2018 Refer note 3	2019 Audited
	Unaddited	Unaddited	Onauditeu	Unaddited	Unauditeu	Auditeu	Unaddited	Unaddited	Relet note 5	Chaudited	Refer fiote 5	Auditeu
a) Segment revenue												
(i) Vaccines	5,552	2,098	2,927	10,132	6,695	9,621	5,553	2,098	2,927	10,133	6,695	9,61
(ii) Formulations (refer note 4)	-	-	-	-	-	-	11,221	10,420	8,111	31,737	26,304	36,05
(iii) Real estate (refer note 5)	-	-	-	-	-	-		-	-	-	-	-
Sub total	5,552	2,098	2,927	10,132	6,695	9,621	16,774	12,518	11,038	41,870	32,999	45,67
Less: Inter segment revenue	-	-	-	-	-	-	-	-	-	-	-	-
Total segment revenue	5,552	2,098	2,927	10,132	6,695	9,621	16,774	12,518	11,038	41,870	32,999	45,67
b) Segment results												1
Profit (+)/ loss (-) before tax		10 1001	(0.505)	(7.004)	40.000			10 0001	10 60 41	10 0001	(100 0000)	
(i) Vaccines	105	(5,455)	(3,585)	(7,231)	(18,614)	3,255	1,033	(6,298)	(2,684)	(6,573)	(17,878)	(1,41
(ii) Formulations (refer note 4)	-	-	-	-	-	-	(2,816)	(750)	1,787	(4,625)	4,013	6,27
(iii) Real estate (refer note 5)	-	-	-	-	-	-	-	-	-	-	(10.000)	-
Sub total	105	(5,455)	(3,585)	(7,231)	(18,614)	3,255	(1,783)	(7,048)	(897)	(11,198)	(13,865)	4,86
Less: Other unallocated expenditure net of unallocated		•	•	-		-	•	-	-	•	-	-
income and exceptional items	105	15 4551	(2 505)	(7 221)	(10 (14)	2 255	(1 702)	(7.040)	(007)	(11 100)	(12 000)	4.00
Total Profit before tax	105	(5,455)	(3,585)	(7,231)	(18,614)	3,255	(1,783)	(7,048)	(897)	(11,198)	(13,865)	4,862
c) Capital employed												
Segment assets												1
(i) Vaccines	68,844	69,704	50,584	68,844	50,584	63,438	69,568	70,420	49,011	69,568	49,011	67,844
(ii) Formulations (refer note 4)	-	-	37,316	-	37,316	-	41,972	43,554	38,554	41,972	38,554	43,065
(iii) Research and Development	-		20,531	-	20,531	-	-	-	20,531	-	20,531	-
(iv) Real estate (refer note 5)	-	-	-	-	-	-	-	-	25,130	-	25,130	-
(v) Unallocated	-	- 1	50,609	-	50,609	-	-	-	16,931		16,931	-
Sub total	68,844	69,704	159,040	68,844	159,040	63,438	111,540	113,974	150,157	111,540	150,157	110,909
Segment liability												
(i) Vaccines	17,616	15,685	6,678	17,616	6,678	80,354	14,011	12,081	5,815	14,011	5,815	76,820
(ii) Formulations (refer note 4)	-	-	15,298	-	15,298	-	99,795	99,984	16,133	99,795	16,133	22,947
(iii) Research and Development	-	-	2,764		2,764			-	2,764	-	2,764	-
(iv) Real estate (refer note 5)	-	-	-	-	-	-	-	-	2,901	-	2,901	-
(v) Unallocated	-	-	111,235	-	111,235	-	-	-	106,867	-	106,867	-
Sub Total	17,616	15,685	135,975	17,616	135,975	80,354	113,806	112,065	134,480	113,806	134,480	99,767
Capital employed (Segment assets - segment liabilities)												
(i) Vaccines	51,228	54,019	43,906	51,228	43,906	(16,916)	55,557	58,339	43,196	55,557	43,196	(8,976
(ii) Formulations (refer note 4)	-	-	22,018	-	22,018	-	(57,823)	(56,430)	22,421	(57,823)	22,421	20,118
(iii) Research and Development	-	-	17,767	-	17,767	-	-		17,767	-	17,767	-
(iv) Real estate (refer note 5)		-	-	-	-	-		-	22,229	-	22,229	-
(v) Unallocated	-	-	(60,626)	-	(60,626)	-		-	(89,936)	-	(89,936)	-
Total capital employed	51,228	54,019	23,065	51,228	23,065	(16,916)	(2,266)	1,909	15,677	(2,266)	15,677	11,142



BAR & Rain

Information relating to discontinued operations as stated in note 4 & 5 to the financial results.

Particulars			Stand	alone		Consolidated						
		Quarter ended			Nine months ended Year ended			d Quarter ended			Nine months ended	
	December	September	December	December	December	March 31,	December	September	December	December	December	March 31
	31, 2019	30, 2019	31, 2018	31, 2019	31, 2018	2019	31, 2019	30, 2019	31, 2018	31, 2019	31, 2018	2019
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	Unaudited	Unaudited	Refer note 3	Unaudited	Refer note 3	Audited
a) Segment revenue												
(i) Formulations (refer note 4)	10,510	9,824	8,167	30,029	25,653	34,795	-	-	-	-	-	
(ii) Real estate (refer note 5)	-	-	-	-	-	-	-	-	-	-	-	
Total	10,510	9,824	8,167	30,029	25,653	34,795		•	-	-	•	
b) Segment results (Profit (+)/ Loss (-) before tax)												
(i) Formulations (refer note 4)	(1,796)	(1,322)	1,674	(3,806)	3,981	958	-					•
(ii) Real estate (refer note 5)	(52)	(148)	(124)	(296)	(302)	(495)	(95)	(259)	(207)	(513)	(444)	(239
Total	(1,848)	(1,470)	1,550	(4,102)	3,679	463	(95)	(259)	(207)	(513)	(444)	(239
c) Segment assets												
(i) Vaccines	3,075	1,315	-	3,075	-	-	3,075	1,315	-	3,075	-	-
(ii) Formulations (refer note 4)	40,286	42,013	-	40,286		41,947			-	-	-	-
(iii) Real estate (refer note 5)	37,168	36,886	-	37,168	-	38,818	28,340	28,037	-	28,340	-	26,644
Total	80,529	80,214	•	80,529		80,765	31,415	29,352	· · ·	31,415	-	26,644
d) Segment liabilities										. 1		
(i) Vaccines	-	-	-	-	-	-	-	-	-	-	-	
(ii) Formulations (refer note 4)	97,838	98,342	-	97,838	-	21,834	-	-	-	-	-	•
(iii) Real estate (refer note 5)	116	145	-	116	-	168	2,846	2,845	•	2,846	-	3,052
Total	97,954	98,487	•	97,954	-	22,002	2,846	2,845		2,846		3,052



Notes:

Bion

Panaces Blot

- The above unaudited financial results of Panacea Biotec Limited ('the Company' or 'PBL') were reviewed by the Audit Committee of the Board and approved by the Board of Directors at their respective meetings held on February 14, 2020. Further, the limited review of the Financial Results for the Quarter and Nine months ended December 31, 2019, in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, has been carried out by the statutory auditors.
- 2. The financial results have been prepared in accordance with the recognition and measurement principles laid down in the IND-AS prescribed under section 133 of the Companies Act, 2013, read with circular no CIR/ CFD/CMD1/44/2019 dated March 29, 2019.
- 3. a. The consolidated financial results of the Company have been prepared by consolidating the Company's financial results for the respective periods with the financial results of the following wholly-owned subsidiaries (collectively, the Company and these subsidiaries hereinafter referred to as the Group) and Joint Venture:
 - Unaudited financial results of Indian subsidiary companies: Ravinder Heights Limited (incorporated on April 15, 2019) and Radhika Heights Limited, Cabana Construction Private Limited, Cabana Structures Limited, Nirmala Buildwell Private Limited, Nirmala Organic Farms & Resorts Private Limited, Radicura Infra Limited and Sunanda Infra Limited (being demerged under the scheme of arrangement as mentioned in note 5 below);
 - (ii) Unaudited financial results of overseas subsidiaries: Panacea Biotec (International) SA and Panacea Biotec Germany GmbH;
 - (iii) Unaudited financial results of Joint Venture: Chiron Panacea Vaccines Private Limited (under liquidation);
 - (iv) Unaudited financial results of Enterprises over which the Company is exercising control: PanEra Biotec Private Limited and Adveta Power Private Limited;
 - (v) Unaudited financial results of overseas subsidiary: Rees Investments Limited (liquidated on May 23, 2019); and
 - (vi) Unaudited financial results of Indian subsidiary companies: Panacea Biotec Pharma Limited (incorporated on March 22, 2019) and Meyten Realtech Private Limited (incorporated on April 12, 2019).
 - b. The Company is presenting the consolidated financial information of the Group and its Joint Venture for the Nine months for the first time. Accordingly, the consolidated amounts for the corresponding quarter and nine months ended December 31, 2018 as reported in the above results have not been subjected to audit or review. However, the management of the Holding Company has exercised necessary due diligence to ensure that the financial results for the said periods provide a true and fair view of the affairs of the Group and its joint venture. The financial results for the said periods been reviewed by the Holding Company's Audit Committee and approved by the Holding Company's Board of Directors.
- 4. On February 26, 2019, as part of the business reorganization, the Board of Directors had approved transfer of pharmaceutical formulations business to its wholly owned subsidiary, Panacea Biotec Pharma Limited ('PBPL'), together with all tangible assets (except R&D center and natural product extraction facility at Lalru) and all intangible assets as specified in the Business Transfer Agreement ("BTA") in relation to the pharmaceutical formulations business including pharmaceutical formulations facility at Baddi, Himachal Pradesh, (referred to as 'Pharma business'), as a going concern through slump sale, with an objective to segregate the different businesses of the Company to ensure smooth functioning of each business in the future. The divestment was approved by the shareholders of the Company in their extra-ordinary general meeting held on March 25, 2019. In order to implement the above transfer, the Company had executed a BTA with PBPL on April 7, 2019.

Accordingly, the activities of the Pharma business of the Company, that are considered as disposal group, are presented as a discontinued operation in the Standalone financial results of the Company in accordance with the provisions of Indian Accounting Standard 105 – 'Non-current Assets Held for Sale and Discontinued Operations'. The net loss from the Pharma business amounting to INR 1,796 lakh for the quarter ended December 31, 2019 (net profit of INR 1,674 lakh for the quarter ended December 31, 2018) and net loss of INR 3,806 Lakh for the nine months ended December 31, 2019 (net profit of INR 3,981 lakh for the nine months ended December 31, 2018) have been presented under 'Net Profit/ (Loss) before tax from discontinued operations' in the Standalone Statement of Financial Results. The assets and liabilities of the Pharma business amounting to INR 40,286 lakh and INR 97,838 lakh respectively are disclosed under the segment assets and liabilities relating to discontinued operations respectively in the Standalone Segment results as at December 31, 2019. PBPL has completed its compliance with the terms and conditions of BTA on February 01, 2020 and consequently the BTA has become effective from that date.

5. On February 26, 2019 and May 30, 2019, the Board of Directors had approved a scheme of arrangement for demerger of its real estate business comprising wholly owned subsidiary Radhika Heights Limited ('RHL') alongwith its step down subsidiaries and two real estate properties from PBL ('Demerged Undertaking') to its wholly-owned subsidiary, Ravinder Heights Limited ('Transferee Company'). Upon implementation of the demerger scheme and completion of related compliances, the Transferee Company shall be listed at the BSE and NSE in compliance with the applicable SEBI Regulations. The Company has received approvals from its shareholders and unsecured creditors in their respective NCLT convened meetings held on January 28, 2020. In accordance with the provisions of Indian Accounting Standard 105 – 'Non-current Assets Held for Sale and Discontinued Operations', the results related to the Demerged Undertaking for the year have been included respectively in the Standalone and Consolidated Statement of Financial Results under 'Net Profit/(Loss) before tax from discontinued operations'. Similarly, the assets and liabilities of the real estate business have been disclosed under the segment assets and liabilities relating to discontinued operations respectively in the Standalone and Consolidated segment results.

1

6. With respect to the observations of the auditors in their report on the above results:

During the financial year 2007-08, the Company had given an advance of INR 1,768 lakh pursuant to the agreement with Ilyas & Mustafa Galadari Management Investment & Development (L.L.C.), U.A.E. ('the Developer') for purchase of certain immoveable properties in Dubai. The Developer failed to deliver the said properties to the Company and offered other properties under construction in lieu of the said properties. Owing to continuous delays in completion of construction, the Company has initiated legal recourse and issued a legal notice to the Developer.

During the quarter ended December 31, 2017, with a view to restructure the Company's debt obligations and reduce its interest outlay, the Board of Directors had approved the assignment of its receivables from the Developer to RHL in lieu of adjustment of part of RHL's loan payable by the Company. The Company has executed the agreement for assignment of this advance to RHL on April 06, 2019. The process of assigning the said receivable to RHL and complying with the applicable provisions of the Foreign Exchange Management Act, 1999 as amended and other applicable laws, is expected to be completed in due course.

In view of ongoing discussions with the Developer and on the basis of the legal advice obtained, the Group believes that it has valid rights to claim the recovery of the advance paid to the Developer, in the form of either a refund or allotment of other properties. The management believes that the advance given to the Developer is fully realisable. Accordingly, no adjustments are considered necessary in the books of accounts.

- 7. For the nine months ended December 31, 2019, the Company has incurred a loss (before tax and exceptional items) of INR 9,793 lakh (2019: loss of INR 27,617 lakh) from the continuing and discontinued operations. The continuous losses had adversely affected the cash flows of the Company. The Company has already taken various measures aimed at improving the financial condition of the Company, inter-alia, raising of funds from the Investors, settling the debts of bankers, repaying the vendor overdue, deploying funds received from the Investors for scaling up its vaccine as well as pharmaceutical formulations business in India and international markets including ROW countries, USA/EU, etc., besides expediting development of new products and monetization of non-core assets. Based on these measures and continuous efforts to improve the business performance, the management believes that it would be able to generate sustainable cash flows, recoup the erosion in its net worth through profitable operations, discharge its obligations as they fall due and has therefore concluding that the going concern assumption continues to be valid.
- The Company is evaluating the impact of section 115BAA of the Income Tax Act, 1961 introduced by the Taxation Laws (Amendment) Ordinance, 2019 with effect from financial year 2019-20.
- 9. The necessary certificate/ report in respect of the above results in terms of requirement of Regulation 33 of the SEBI (Listing Obligations and Other Disclosure Requirements) Regulations, 2015, has been placed before the Board of Directors.
- 10. Previous period amounts have been regrouped/ reclassified in compliance with IND-AS to make them comparable with those of current period/ year.
- 11. '0' under "Rs. in Lakh" represents amount less than Rs.50,000. Further, the figures shown in the tables may not exactly add up due to rounding off.
- 12. The above results are also available on the Company's website http://www.panaceabiotec.com

For and on behalf of the Board of Directors

Dr. Rajesh Jain Managing Director

Place: New Delhi Date: February 14, 2020



Panacea Biotec Limited

Regd. Office: Ambala-Chandigarh Highway, Lalru-140501, Punjab CIN: L33117PB1984PLC022350, Ph. No. +91-11-41679000, Fax: +91-11-41679070 Website: <u>http://www.panaceabiotec.com</u>, E-mail: <u>corporate@panaceabiotec.com</u>

Walker Chandiok & Co LLP (Formerly Walker, Chandiok & Co) L-41 Connaught Circus New Delhi 110001 India

T +91 11 4278 7070 F +91 11 4278 7071

Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results and Year to Date Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Panacea Biotec Limited

- 1. We have reviewed the accompanying statement of standalone unaudited financial results ('the Statement') of Panacea Biotec Limited ('the Company') for the quarter ended 31 December 2019 and the nine months results for the period 1 April 2019 to 31 December 2019, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the SEBI from time to time.
- 2. The Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under Section 133 of the Companies Act, 2013 ('the Act'), and as per the presentation requirements of SEBI Circular CIR/CFD/FAC/62/2016 dated 5 July 2016, (hereinafter referred to as 'the SEBI Circular'), and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



FOR IDENTIFICATION PURPOSES ONLY

Chartered Accountants

Offices in Bongaluru, Chandigarh Chennai, Gurgaon, Hyderabad, Kolkata, Mumbai, New Delhi, Noida and Pune



Walker Chandiok & Co LLP is registered with limited liability with identification number AAC-2085 and its registered office at L-41 Connaught Circus, New Delhi, 110001, India

Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results and Year to Date Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (Cont'd)

- 4. Based on our review conducted as above nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Act, and as per the presentation requirements of the SEBI Circular, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.
- 5. We draw attention to Note 6 to the Statement regarding capital advances amounting to ₹1,768 lakhs given to a real estate developer for acquiring certain immovable properties in Dubai where the company has initiated legal recourse. Our conclusion is not modified in respect of this matter.

For Walker Chandiok & Co LLP Chartered Accountants Firm Registration No: 001076N/N500013

Anupam Kumar Parther Membership No. 501531

UDIN No.: 20501531AAAABL2270

Place: New Delhi Date: 14 February 2020

Standard August Angel

FOR IDENTIFICATION PURPOSES ONLY



Walker Chandiok & Co LLP (Formerly Walker, Chandiok & Co) L-41 Connaught Circus New Delhi 110001 India

T +91 11 4278 7070 F +91 11 4278 7071

Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results and Year to Date Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Panacea Biotec Limited

- 1. We have reviewed the accompanying statement of unaudited consolidated financial results ('the Statement') of Panacea Biotec Limited ('the Holding Company') and its subsidiaries (the Holding Company and its subsidiaries together referred to as 'the Group') and its joint venture (refer Annexure 1 for the list of subsidiaries and joint venture included in the Statement) for the quarter ended 31 December 2019 and the consolidated nine months results for the period 1 April 2019 to 31 December 2019, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 (as amended), including relevant circulars issued by the SEBI from time to time. Attention is drawn to the fact that the consolidated figures for the corresponding quarter ended 31 December 2018 and the corresponding period from 1 April 2018 to 31 December 2018, as reported in the Statement have been approved by the Holding Company's Board of Directors but have not been subjected to audit or review.
- 2. This Statement, which is the responsibility of the Holding Company's management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and as per the presentation requirements of SEBI Circular CIR/CFD/FAC/62/2016 dated 5 July 2016 (hereinafter referred to as 'the SEBI Circular', and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the SEBI Circular CIR/CFD/CMD1/44/2019 dated 29 March 2019 issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), to the extent applicable.



FOR IDENTIFICATION PURPOSES ONLY

Rinte



Offices in Bengaluru, Chandigath Chonnal, Gurgeon, Hyderabad, Kolkata, Mumbel, New Delhi, Noida and Pune

Walker Chandick & Co LLP is registered with limited liability with identification number AAC-2085 and its registered office at L41 Connaught Circus, New Delhi, 110001, India

Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results and Year to Date Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (Cont'd)

- 4. Based on our review conducted and procedures performed as stated in paragraph 3 above and upon consideration of the review reports of other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Act, and as per the presentation requirements of the SEBI Circular and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.
- 5. We draw attention to Note 6 to the Statement regarding capital advances amounting to ₹1,768 lakhs given to a real estate developer for acquiring certain immovable properties in Dubai where the company has initiated legal recourse. Our conclusion is not modified in respect of this matter.
- 6. We did not review the interim financial results of nine subsidiaries included in the Statement, whose financial information reflects total revenues of ₹798 lakhs and ₹1,943 lakhs, total net profit after tax of ₹242 lakhs and ₹385 lakhs, total comprehensive income of ₹242 lakhs and ₹385 lakhs, for the quarter and nine months period ended on 31 December 2019, respectively. These interim financial results have been reviewed by other auditors whose review reports have been furnished to us by the management, and our conclusion in so far as it relates to the amounts and disclosures included in respect of these subsidiaries and joint venture is based solely on the review reports of such other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion is not modified in respect of this matter.

7. The Statement includes the interim financial results of five subsidiaries, which have not been reviewed by their auditors, whose interim financial results reflects total revenues of ₹5 lakhs and ₹18 lakhs, net profit after tax of ₹1 lakhs and ₹3 lakhs, total comprehensive income of ₹1 lakhs and ₹3 lakhs for the quarter and nine months period ended 31 December 2019 respectively, as considered in the Statement. The Statement also includes the Group's share of net profit after tax of ₹7 lakhs and ₹17 lakhs, and total comprehensive income of ₹7 lakhs and ₹17 lakhs for the quarter and nine months period ended on 31 December 2019 respectively, in respect of one joint venture, based on their interim financial results, which have not been reviewed by their auditors, and have been furnished to us by the Holding Company's management. Our conclusion on the Statement, and our report in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), read with SEBI Circular, in so far as it relates to the aforesaid subsidiaries and joint venture, are based solely on such unreviewed interim financial results. According to the information and explanations given to us by the management, these interim financial results are not material to the Group.

Our conclusion is not modified in respect of this matter.

For Walker Chandiok & Co LLP Chartered Accountants Firm Registration No: 001076N/N500013

Invel

Anupam Kumar Partner Membership No. 501531

UDIN No.: 20501531AAAABM6294

Place: New Delhi Date: 14 February 2020 HAR CHANDION



FOR IDENTIFICATION

PURPOSES ONLY

Chartered Accountants

Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results and Year to Date Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (Cont'd)

Annexure 1

List of entities included in the Statement

Name of the Entity	Nature of Relationship
Panacea Biotec Limited	Holding Company
Radhika Heights Limited	Subsidiary Company
Rees Investment Limited	Subsidiary Company (liquidated on 23 May 2019)
Panacea Biotec (International) SA	Subsidiary Company
PanEra Biotec Private Limited	Subsidiary Company
Panacea Biotec Pharma Limited	Subsidiary Company
Ravinder Heights Limited	Subsidiary Company
Meyten Realtech Private Limited	Subsidiary Company
Adveta Power Private Limited	Step down Subsidiary
Cabana Construction Private Limited	Step down Subsidiary
Cabana Structures Private Limited	Step down Subsidiary
Nirmala Buildwell Private Limited	Step down Subsidiary
Nirmala Organic Farms and Resorts Private Limited	Step down Subsidiary
Radicura Infra Limited	Step down Subsidiary
Sunanda Infra Limited	Step down Subsidiary
Panacea Biotec Germany Gmbh	Step down Subsidiary
Chiron Panacea Vaccines Private Limited	Joint venture



FOR IDENTIFICATION PURPOSES ONLY



Chartered Accountants